AT 101 - AbClonAlternative Names: AT-101 - AbClon; AT101
Latest Information Update: 08 Jul 2016
At a glance
- Originator AbClon
- Class CAR-T cell therapies
- Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 30 Jun 2016 Preclinical trials in Haematological malignancies in South Korea (Parenteral)